Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px
Document › Details

Selvita S.A.. (2/6/18). "Press Release: Selvita Appoints Steffen Heeger, M.D., PhD as Chief Medical Officer". Kraków.

Organisations Organisation Selvita S.A. (WSE:SLV)
  Group Selvita (Group)
  Organisation 2 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group MorphoSys (Group)
Products Product SEL24 (MEN1703) (dual PIM/FLT3 kinase inhibitor, Selvita / Menarini)
  Product 2 RVU120 (Ryvu) (formerly SEL120 (Selvita))
Persons Person Heeger, Steffen (Selvita 201802– CMO before MorphoSys 201312– Head of Clinical Research before Merck Serono)
  Person 2 Przewiezlikowski, Pawel (Selvita 201309 CEO + Co-Founder)

Selvita S.A. (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer.

Dr. Heeger will join Selvita in February and will be responsible for all clinical, medical affairs and regulatory functions for Selvita oncology pipeline including SEL24, the first-in-class dual PIM/FLT3 kinase inhibitor currently in Phase I/II studies in acute myeloid leukemia, SEL120, the first-in-class selective CDK8 kinase inhibitor, targeting hematological malignancies and solid tumors, currently in IND-enabling studies as well as new programs emerging from three Selvita’s discovery platforms – targeted therapeutics, cancer metabolism and immunometabolism, and immune-oncology.

Dr. Steffen Heeger is an oncologist with a thorough experience in oncology drug development. Prior to joining Selvita, Dr. Heeger held a position of Vice President, Head of Clinical Development and Head of Clinical Operations at Morphosys AG, where he focused on the development and execution of clinical strategy for Morphosys’ lead hematology and oncology products.

Dr. Heeger’s previous experience includes also a nine-year tenure at Merck Serono, where he was Head of Medical Affairs and led the Global Clinical Development Team for Erbitux®.

Dr. Heeger studied Medicine in Freiburg, Heidelberg and Mannheim and continued his medical training at the Department of Hematology and Oncology of the University Hospital in Heidelberg. Simultaneously with his medical training as a Physician, he also held the position of a Scientist at the German Cancer Research Center (DKFZ) in Heidelberg where he worked on the development of antibody conjugates. He received a PhD in Medicine from the University of Heidelberg.

“We are thrilled to have Dr. Steffen Heeger join the senior management team at Selvita. The wealth of experience he brings in to our company is invaluable, with his track record in clinical development of oncohematology drugs including biologics bringing to us great value added, especially considering our ambitious development strategy for 2017-2021." - comments Pawel Przewiezlikowski, Chief Executive Officer at Selvita. "Dr. Heeger’s appointment will have a considerable impact on our clinical capabilities and strategy, as well as it underscores our strong commitment to the further development and expansion of our clinical portfolio, with SEL120 managed internally in collaboration with Leukemia and Lymphoma Society and SEL24 developed with our partner Menarini Group, as two highly promising potential treatments for AML patients.”

About Selvita

Selvita is a drug discovery company, developing breakthrough therapies in the area of oncology. The company’s most advanced program, SEL24, has been licensed to Menarini Group and is currently in Phase I studies in AML. Other projects include SEL120, a first-in-class small molecule inhibitor of CDK8 in preclinical studies, several drug discovery platforms in immuno-oncology, immunometabolism and cancer metabolism, as well as epigenetics, performed independently or in collaboration with global pharma and biotech companies.

Selvita also offers a broad range of integrated drug discovery services, helping biotech and pharma partners discover and develop new drugs.

The company has alliances and partnerships with more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe, including R&D partnerships with Menarini Group, Leukemia and Lymphoma Society, Merck, H3 Biomedicine, and Nodthera.

The company was established in 2007 and currently employs over 440 scientists, among which 30% are PhDs. Selvita is headquartered in Krakow with second research site in Poznan, Poland and international offices located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK. Selvita is listed on the Warsaw Stock Exchange (WSE:SLV).


Natalia Baranowska
+48 784 069 418

Record changed: 2019-04-26


Picture [iito] Made Without Love 650x80px

More documents for Selvita (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC C Lee Hood Speaking 650x300px

» top